Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 142 clinical trials
RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS (RAM-MS)

This study is a randomized multicentre, multinational, treatment interventional study of RRMS patients with breakthrough inflammatory disease activity in spite of ongoing standard immunomodulatory medication. The study has two treatment arms; arm A: HSCT (hematopoietic stem cell transplantation) and arm B: alemtuzumab, a registered immunomodulatory treatment of RRMS. A pre-planned …

cyclophosphamide
interferon
MRI
alemtuzumab
teriflunomide
  • 35 views
  • 09 Apr, 2022
  • 7 locations
A Phase 2 Study of Home Care Following Autologous Hematopoietic Stem Cell Transplantation

This is a research study to compare the well-being (caregiver strain index) of caregivers of patients receiving home vs standard care after autologous hematopoietic stem cell transplant.

  • 9 views
  • 23 Mar, 2022
  • 1 location
Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis

fecal microbiota (FMT) can improve the outcome of autologous hematopoietic stem cell transplantation (autoHSCT) by increasing the disease-free period and disease progression suspension for at least 5

cyclophosphamide
rituximab
disease or disorder
  • 0 views
  • 21 Feb, 2022
  • 1 location
Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma (TMI-ASCT)

The investigators hypothesize that conformal radiation will allow the administration of higher doses of external beam radiation to marrow based malignancies than total body irradiation (TBI)without increasing the toxicity to normal tissues beyond that induced by TBI. Further,the investigators hypothesize that this will result in an improvement in disease response …

cancer
chemotherapy regimen
refractory multiple myeloma
cell transplantation
  • 9 views
  • 23 Jan, 2022
  • 1 location
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell

b-cell lymphoma
rituximab
remission
  • 0 views
  • 22 Mar, 2022
  • 1 location
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis

in usual care: upfront autologous HSCT versus usual care with (intravenous (i.v.) cyclophosphamide (CYC) pulse therapy followed by mycophenolate mofetil (MMF) and HSCT as rescue option).

diffuse cutaneous systemic sclerosis
hypertension
MRSS
raynaud's syndrome
cyclophosphamide
  • 0 views
  • 18 Dec, 2021
  • 5 locations
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation

Higher gut microbiome diversity has been associated with improved survival following autologous stem cell transplantation in multiple myeloma and lymphoma, but no strategies have been identified

  • 0 views
  • 29 Apr, 2022
  • 1 location
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

significant comorbidities not eligible for autologous stem cell transplantation (ASCT): bortezomib-melphalan-prednisone (VMP), melphalan-prednisone-thalidomide (MPT) and lenalidomide with low-dose

plasmacytoma
bone marrow procedure
ejection fraction
serum calcium
cancer
  • 4 views
  • 19 Jun, 2022
  • 1 location
EDIT-301 for Autologous HSCT in Subjects With Severe Sickle Cell Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).

busulfan
vaso-occlusive crisis
hydroxyurea
  • 0 views
  • 13 Jun, 2022
  • 13 locations
Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) (BASALT)

or cure without autologous stem cell transplantation.

classical hodgkin lymphoma
brentuximab
platelet count
lymphoma
measurable disease
  • 3 views
  • 04 Feb, 2022
  • 2 locations